Recent updates from the Centers for Medicare & Medicaid Services (CMS) have outlined a new framework that integrates specific cannabinoid products into federal healthcare models. Under a new pilot initiative, eligible healthcare providers will have the option to furnish up to $500 worth of hemp-derived CBD and THC products annually to qualifying Medicare patients.
This policy operates through the Substance Access Beneficiary Engagement Incentive (BEI). It is designed to evaluate how these products might help manage symptoms for patients dealing with complex or chronic conditions. The program relies on participating provider groups, rather than direct Medicare billing, to fund and distribute the items.
This initiative highlights a change in how federal health entities approach hemp-derived treatments in clinical settings. By creating guidelines for product quality, dosage, and patient eligibility, CMS aims to bring current consumer use into a more regulated and physician-monitored framework.
Substance Access BEI Program
The Substance Access Beneficiary Engagement Incentive is an optional program for healthcare organizations participating in certain CMS Innovation Center models. It allows these participating providers to consult with eligible Medicare beneficiaries about using hemp products for symptom control.
A critical distinction of this program is its funding structure. Medicare does not directly pay the provider or the patient for the CBD or THC products. Beneficiaries are specifically instructed not to submit a Medicare claim for reimbursement.
Instead, the participating Accountable Care Organizations (ACOs) or oncology practices elect to fund the products themselves as part of their strategy to improve patient outcomes and manage chronic conditions effectively.
By utilizing the BEI framework, CMS permits these healthcare organizations to legally and formally integrate cannabinoid discussions and provisions into their care plans without violating Medicare billing protocols.
Participating CMS Innovation Center Models
The Substance Access BEI is not a blanket benefit available to all Medicare enrollees nationwide. It is restricted to patients aligned with healthcare providers participating in three specific CMS Innovation Center models.
ACO REACH Model
The Accountable Care Organization Realizing Equity, Access, and Community Health (ACO REACH) Model involves groups of doctors, hospitals, and other healthcare providers who collaborate to give coordinated high-quality care to Medicare patients. Participants in this model can begin offering the Substance Access BEI starting April 1, 2026.
Enhancing Oncology Model (EOM)
The Enhancing Oncology Model focuses specifically on improving cancer care. It incentivizes oncology practices to deliver patient-centered, coordinated care for individuals receiving systemic chemotherapy.
Given that cancer patients often seek alternative symptom management for pain and nausea, this model is a logical fit for the BEI. Like ACO REACH, EOM participants can utilize the BEI starting April 1, 2026.
Long-term Enhanced ACO Design (LEAD) Model
The LEAD Model is an upcoming 10-year initiative designed to support independent practices and providers serving high-needs patients, including those dually eligible for Medicare and Medicaid.
Providers participating in the LEAD Model will have access to the Substance Access BEI beginning January 1, 2027.
Patient Eligibility Requirements
Even if a patient receives care from a participating ACO or oncology practice, they must meet specific clinical criteria to receive hemp products through the program. CMS has established several safeguards to prioritize patient safety.
To be eligible, a beneficiary must be at least 18 years old. They cannot meet the specific frailty exclusions outlined by their respective care model, nor can they have certain disqualifying medical conditions designed to prevent adverse health events. Additionally, individuals who are pregnant or breastfeeding are excluded from the program.
The most important requirement involves direct clinical oversight. A qualified physician must determine that the use of hemp products is medically appropriate for the patient. The physician is required to document a shared decision-making process.
This mandatory discussion must cover the potential benefits and risks of the products, the patient’s personal health goals, and a review of the patient’s current medications to prevent dangerous drug interactions.
Strict Rules for Eligible Hemp Products
CMS has set highly specific parameters regarding what types of CBD and THC products can be distributed. Providers cannot simply hand out any commercially available item.
Chemical Composition and Dosage
Eligible products must meet the federal definition of legal hemp, meaning they contain no more than 0.3 percent delta-9 THC. However, CMS goes a step further by capping the total amount of tetrahydrocannabinols at 3 milligrams per serving. This 3 mg limit includes delta-8 THC, delta-10 THC, and THCA.
Furthermore, the products must exclusively contain naturally occurring cannabinoids from the cannabis plant. The program strictly prohibits synthetic or chemically altered cannabinoids.
Administration Methods
The program expressly excludes all inhalable products. Beneficiaries cannot receive smokable hemp flower or vaping devices. Providers must furnish all products in an orally administered form, such as oils, tinctures, or capsules.
Procurement and Safety Standards
Participating organizations cannot simply tell a patient to buy a product at a local retail store and bring back a receipt. A qualified physician affiliated with the participating organization must furnish the eligible hemp products directly.
Providers are responsible for their own procurement, which involves contracting with legally compliant, high-quality farms consistent with 2018 Farm Bill requirements. Every product must undergo third-party testing to ensure accurate cannabinoid potency and to confirm the absence of contaminants and microbial hazards.
Navigating Changing Federal Regulations and Next Steps in Cannabinoid Care
Current federal healthcare and cannabinoid policy is complex. CMS has acknowledged that this program operates strictly within the confines of the 2018 Farm Bill’s hemp provisions. It does not override the Controlled Substances Act, nor does it authorize the use of Schedule I which medical marijuana still currently falls under.
Participants must also ensure that the products comply with all applicable state and local laws. Because many states have enacted their own restrictions on hemp-derived cannabinoids, availability will vary depending on geography.
CMS has clearly stated that if federal legal limits on hemp-derived products change in the future, the agency will automatically adjust its definition of eligible products to remain in compliance with the law.
The introduction of the Substance Access BEI represents an effort to gather real-world data on how patients use hemp-derived products for symptom management. By structuring this access through established Innovation Center models, healthcare authorities can observe outcomes while maintaining clinical oversight.
